Literature DB >> 9279883

Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine.

S D Raeissi1, Z Guo, G L Dobson, P Artursson, I J Hidalgo.   

Abstract

PURPOSE: To compare the activity of the CYP3A enzyme expressed by TC7, a cell culture model of the intestinal epithelial cell, to the activity of human intestinal CYP3A4, using terfenadine as a substrate.
METHODS: The metabolism of terfenadine was investigated in intact cells and microsomal preparations from TC7, human intestine, and liver. The effect of two CYP3A inhibitors, ketoconazole and troleandomycin (TAO), on the metabolism of terfenadine was also examined.
RESULTS: Only hydroxy-terfenadine was detected in TC7 microsomal incubations. In contrast, azacyclonol and hydroxy-terfenadine were detected in human intestinal and hepatic microsomal incubations. The Km values for hydroxy-terfenadine formation in TC7 cells, intestine and liver microsomes were 1.91, 2.5, and 1.8, microM respectively. The corresponding Vmax values were 2.11, 61.0, and 370 pmol/min/mg protein. Km values for azacyclonol in intestinal and hepatic samples were 1.44 and 0.82 microM and the corresponding Vmax values were 14 and 60 pmol/min/mg protein. The formation of hydroxy-terfenadine was inhibited by ketoconazole and TAO in human intestine and TC7 cell microsomes. The Km and Vmax values for terfenadine metabolism in intact TC7 cells were similar to those from TC7 cell microsomes.
CONCLUSIONS: Our results indicate that TC7 cells are a potentially useful alternative model for studies of CYP3A mediated drug metabolism. The CYP3A expressed by TC7 cells is not CYP3A4, but probably CYP3A5, making this cell line suitable for studies of colonic drug transport and metabolism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9279883     DOI: 10.1023/a:1012197110917

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

Review 1.  Cell cultures as models for drug absorption across the intestinal mucosa.

Authors:  P Artursson
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1991       Impact factor: 4.889

2.  Expression of cytochrome P-450 3A in HT29-MTX cells and Caco-2 clone TC7.

Authors:  V Carrière; T Lesuffleur; A Barbat; M Rousset; E Dussaulx; P Costet; I de Waziers; P Beaune; A Zweibaum
Journal:  FEBS Lett       Date:  1994-12-05       Impact factor: 4.124

Review 3.  The use of cultured epithelial and endothelial cells for drug transport and metabolism studies.

Authors:  K L Audus; R L Bartel; I J Hidalgo; R T Borchardt
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

4.  CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines.

Authors:  L Gervot; V Carrière; P Costet; P H Cugnenc; A Berger; P H Beaune; I de Waziers
Journal:  Environ Toxicol Pharmacol       Date:  1996-12-20       Impact factor: 4.860

5.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

Authors:  J C Gorski; S D Hall; D R Jones; M VandenBranden; S A Wrighton
Journal:  Biochem Pharmacol       Date:  1994-04-29       Impact factor: 5.858

6.  Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation.

Authors:  C H Yun; R A Okerholm; F P Guengerich
Journal:  Drug Metab Dispos       Date:  1993 May-Jun       Impact factor: 3.922

7.  Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.

Authors:  M Jurima-Romet; K Crawford; T Cyr; T Inaba
Journal:  Drug Metab Dispos       Date:  1994 Nov-Dec       Impact factor: 3.922

8.  Biochemical characterization of resistance to mitoxantrone and adriamycin in Caco-2 human colon adenocarcinoma cells: a possible role for glutathione S-transferases.

Authors:  W H Peters; H M Roelofs
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

9.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

Authors:  J C Kolars; P Schmiedlin-Ren; J D Schuetz; C Fang; P B Watkins
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

10.  In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.

Authors:  A D Rodrigues; D J Mulford; R D Lee; B W Surber; M J Kukulka; J L Ferrero; S B Thomas; M S Shet; R W Estabrook
Journal:  Drug Metab Dispos       Date:  1995-07       Impact factor: 3.922

View more
  2 in total

1.  The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.

Authors:  J J Miceli; M Smith; L Robarge; T Morse; A Laurent
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

2.  Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.

Authors:  S D Raeissi; I J Hidalgo; J Segura-Aguilar; P Artursson
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.